| P/E (FY) | 6.0 | Sales (TTM) | $5.8M |
| Earnings (TTM) | $66.1M | ROE | 70.05% |
| Net Margin | 1223.08% | ROIC | — |
| Debt / Equity | 0.13 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 60.26% |
| Market Cap | $343.1M | Trading Days | 2524 |
| 52W High | 7.54 |
| 52W Low | 4.00 |
| % Off High | −20.16% |
| YTD | 14.23% | 1Y | −9.06% |
| 3Y | 70.54% | 5Y | −81.19% |
| 10Y | −90.59% | Since incept. (ann.) | −20.36% |
License 58% · Product 42%
| Ann. Volatility (1Y) | 52.38% | Ann. Volatility (3Y) | 68.75% |
| Sharpe (1Y) | 0.07 | Sharpe (3Y) | 0.67 |
| Max Drawdown (1Y) | −42.32% | Max Drawdown (3Y) | −63.48% |
| Beta (3Y, vs SPY) | 1.85 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| RCKT | ROCKET PHARMACEUTICALS, INC. | $342.9M | — |
| AKBA | Akebia Therapeutics, Inc. | $340.7M | — |
| UPB | Upstream Bio, Inc. | $348.3M | — |
| DMAC | DiaMedica Therapeutics Inc. | $357.8M | — |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $328.9M | — |
| CATX | Perspective Therapeutics, Inc. | $327.3M | — |
| CTNM | Contineum Therapeutics, Inc. | $327.1M | — |
| AVIR | Atea Pharmaceuticals, Inc. | $360.9M | — |
| ORGO | Organogenesis Holdings Inc. | $325.5M | 16.9 |
| NATR | NATURES SUNSHINE PRODUCTS INC | $364.7M | 19.6 |
| ENTA | ENANTA PHARMACEUTICALS INC |
| $366.7M |
| — |
| PRLD | Prelude Therapeutics Inc | $369.6M | — |
